Adlai Nortye Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adlai Nortye Ltd (ANL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adlai Nortye Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 6M vs 153,563M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+115.4%) for its tracked peer group.
- Profitability: Its -549.0% net margin compares with 15.8% for the peer group.
- Scale: Adlai Nortye Ltd ranks #125 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Adlai Nortye Ltd accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.05M compares with $1.02M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ANL Sales vs. its Competitors, Q4 2025
With a net margin of -548.95 %, Adlai Nortye Ltd reported lower profitability than its competitors (15.79 %).
Adlai Nortye Ltd generated 0.01 % of the combined sales of its peer group.
Adlai Nortye Ltd vs. its Competitors, Q4 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adlai Nortye Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adlai Nortye Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adlai Nortye Ltd's competitor groups requires a Commercial License.
Adlai Nortye Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adlai Nortye Ltd | - | - | - | Yes |
| Competitors combined (155) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ANL Stock Performance relative to its Competitors
ANL Stock Performance relative to High-Confidence Competitors
ANL Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Erasca Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 4 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 5 | Climb Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adlai Nortye Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Adlai Nortye Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Adlai Nortye Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Adlai Nortye Ltd | 1,511.75 | 6.47 |
| Astrazeneca Plc | 246,327.40 | 58,739.00 |
| Vertex Pharmaceuticals Inc | 129,320.05 | 12,587.20 |
| Bristol myers Squibb Company | 125,870.08 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 77,889.86 | 15,534.70 |
| Zai Lab Limited | 28,482.82 | 449.61 |
| SUBTOTAL | 822,679.60 | 154,868.27 |
Sign in to see all competitors of Adlai Nortye Ltd.
Sources: Adlai Nortye Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adlai Nortye Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adlai Nortye Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Betta Pharmaceuticals Co., Ltd. | Named by the company | 85% |
| Keythera (Suzhou) Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Tempest Therapeutics Inc. | Named by the company | 85% |
| Amgen Inc. | Named by the company | 85% |
| Incyte | Named by the company | 85% |
| Shanghai Yuyao Biotech Ltd. | Named by the company | 85% |
| Chase Sun Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Maxinovel Pharmaceuticals Co., Ltd. | Named by the company | 85% |
| Silexion Therapeutics Corp | Named by the company | 85% |
| Ascletis Pharma Inc. | Named by the company | 85% |
| Innate Pharma S.A./AstraZeneca PLC | Named by the company | 85% |
| Shenzhen Ionova Life Science Co., Ltd. | Named by the company | 85% |
| Abbisko Cayman Ltd. | Named by the company | 85% |
| Chemocentryx Inc. | Named by the company | 85% |
| Rottapharm Biotech S.r.l. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Adlai Nortye Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Adlai Nortye Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Incyte Corporation | Reportable 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Protagonist Therapeutics inc | Single reportable segment 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Adlai Nortye Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adlai Nortye Ltd | 1,512 | 52,618 | -288,846 |
| Astrazeneca Plc | 246,327 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 129,320 | 31,079,506 | 10,877,037 |
| Bristol myers Squibb Company | 125,870 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 77,890 | 1,008,092 | 280,902 |
| Zai Lab Limited | 28,483 | 252,026 | -105,501 |
| PEERS TOTAL | 821,168 | 1,016,387 | 145,110 |
Adlai Nortye Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Incyte Corporation | United States 93.16 % |
| Xoma Royalty Corporation | CH 54.36 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adlai Nortye Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Adlai Nortye Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Adlai Nortye Ltd ranks #125 of 498 companies by market capitalization in its industry, holding 0.03 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 816, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,029,931 | 19.10 % |
| 2 | Johnson and Johnson | 643,198 | 11.93 % |
| 3 | Beone Medicines Ltd | 553,175 | 10.26 % |
| 4 | Abbvie Inc | 461,540 | 8.56 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 125 | Adlai Nortye Ltd | 1,521 | 0.03 % |
Market cap and industry share for the rest of Adlai Nortye Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-01.
Adlai Nortye Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 120 | Ani Pharmaceuticals Inc | 1,598 | -20.40 % |
| 121 | Ultragenyx Pharmaceutical Inc | 1,549 | -49.45 % |
| 122 | Silence Therapeutics Plc | 1,548 | 110.50 % |
| 123 | Uniqure N v | 1,547 | -57.77 % |
| 124 | Innoviva Inc | 1,234 | 12.3% |
| 125 | Adlai Nortye Ltd | 1,521 | 781.60 % |
| 126 | Tyra Biosciences Inc | 1,234 | 12.3% |
| 127 | Phibro Animal Health Corporation | 1,234 | 12.3% |
| 128 | Oric Pharmaceuticals Inc | 1,234 | 12.3% |
| 129 | Arrivent Biopharma inc | 1,234 | 12.3% |
| 130 | Gh Research Plc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Adlai Nortye Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-01. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Adlai Nortye Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (345 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 63.93 % (avg) | -63.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -7.12 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 2.89 % | 4.90 % (avg) | -2.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Adlai Nortye Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | -17.5x | 4.5x | -22.0x |
| Return on Equity | 426.92 % | industry aggregate | 400.67 % |
| Return on Invested Capital | 230.06 % | -2.85 % (avg) | 232.91 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adlai Nortye Ltd's BCG Growth-Share Matrix
Relative market share (vs Adlai Nortye Ltd's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Adlai Nortye Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Adlai Nortye Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 816 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.89 % vs industry average 4.90 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Adlai Nortye Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Adlai Nortye Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Adlai Nortye Ltd's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Adlai Nortye Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Adlai Nortye Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 400.7 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (46.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Adlai Nortye Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adlai Nortye Ltd | 0.19 | 0.65 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Zai Lab Limited | 1.66 | 2.45 | 0.31 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adlai Nortye Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adlai Nortye Ltd | Q4 2025 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Zai Lab Limited | Q2 2026 | -3.3 % | - |
| PEERS TOTAL | +9.7 % | +83.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adlai Nortye Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adlai Nortye Ltd | Q4 2025 | - | +10.0 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Zai Lab Limited | Q2 2026 | +12.0 % | -53.5 % |
Adlai Nortye Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adlai Nortye Ltd | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Zai Lab Limited | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adlai Nortye Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adlai Nortye Ltd | - | 233.58 |
| Astrazeneca Plc | 24.09 | 4.19 |
| Vertex Pharmaceuticals Inc | 29.55 | 10.27 |
| Bristol myers Squibb Company | 13.53 | 2.56 |
| Regeneron Pharmaceuticals Inc | 18.20 | 5.01 |
| Zai Lab Limited | - | 63.35 |
| PEERS AVERAGE | 37.27 | 5.31 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.